Heterocyclic compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-9359365-B2
Application number	US-201414506429-A
Country	US
Kind code	B2
Filing date	Oct 3, 2014
Priority date	Oct 4, 2013
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

First claim

What is claimed is:

1. A compound of the formula:

or a pharmaceutically acceptable form thereof, wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, or a mixture of enantiomers.

2. The compound of claim 1 , wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt, enantiomer, or a mixture of enantiomers.

3. A compound of the formula:

4. A compound of the formula:

or a pharmaceutically acceptable form thereof, wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt, hydrate, or solvate.

5. The compound of claim 4 , wherein the pharmaceutically acceptable form is a pharmaceutically acceptable salt.

6. A compound of the formula:

7. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 55%.

8. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 75%.

9. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 90%.

10. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 95%.

11. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 98%.

12. The compound of claim 2 , wherein the compound has an (S)-enantiomeric excess of greater than 99%.

13. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable excipients.

14. A pharmaceutical composition comprising a compound of claim 2 and one or more pharmaceutically acceptable excipients.

15. A pharmaceutical composition comprising a compound of claim 3 and one or more pharmaceutically acceptable excipients.

16. A pharmaceutical composition comprising a compound of claim 4 and one or more pharmaceutically acceptable excipients.

17. A pharmaceutical composition comprising a compound of claim 5 and one or more pharmaceutically acceptable excipients.

18. A pharmaceutical composition comprising a compound of claim 6 and one or more pharmaceutically acceptable excipients.

19. A pharmaceutical composition comprising a compound of claim 7 and one or more pharmaceutically acceptable excipients.

20. A pharmaceutical composition comprising a compound of claim 8 and one or more pharmaceutically acceptable excipients.

21. A pharmaceutical composition comprising a compound of claim 9 and one or more pharmaceutically acceptable excipients.

22. A pharmaceutical composition comprising a compound of claim 10 and one or more pharmaceutically acceptable excipients.

23. A pharmaceutical composition comprising a compound of claim 11 and one or more pharmaceutically acceptable excipients.

24. A pharmaceutical composition comprising a compound of claim 12 and one or more pharmaceutically acceptable excipients.

Assignees

• Infinity Pharmaceuticals Inc

Inventors

• Castro Alfredo C
• Evans Catherine A
• Janardanannair Somarajannair
• Lescarbeau Andre
• Liu Tao
• Tremblay Martin R

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title